The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Open accessAbstract
Heart failure affects ≈5.7 million people in the United States alone. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists have improved mortality in patients with heart failure and reduced ejection fraction, but mortality remains high. In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular complex. Sacubitril is converted by esterases to LBQ657, which inhibits neprilysin, the enzyme responsible for the degradation of the natriuretic peptides and many other vasoactive peptides. Thus, this combined angiotensin receptor antagonist and neprilysin inhibitor addresses 2 of the pathophysiological mechanisms of heart failure: activation of the renin-angiotensin-aldosterone system and decreased sensitivity to natriuretic peptides. In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, valsartan/sacubitril significantly reduced mortality and hospitalization for heart failure, as well as blood pressure, compared with enalapril in patients with heart failure, reduced ejection fraction, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriuretic peptide. Ongoing clinical trials are evaluating the role of valsartan/sacubitril in the treatment of heart failure with preserved ejection fraction and hypertension. We review here the mechanisms of action of valsartan/sacubitril, the pharmacological properties of the drug, and its efficacy and safety in the treatment of heart failure and hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 1×
“The mechanisms of action of ARBs such as valsartan have been studied extensively, are reviewed elsewhere, and are not addressed in detail here.(4) In brief, ARBs decrease vasoconstriction and aldosterone production and increase natriuresis by gest on July (2)2, 2018 http://ciajournals.”
BackgroundBrown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313
Self-citationIncidence and Characteristics of Angioedema Associated With Enalapril
Kostis, J. B., Kim, H. J., Rusnak, J., Casale, T., Kaplan, A., Corren, J., & Levy, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1637 · Cited by 291
Pretorius, M., Rosenbaum, D., Vaughan, D. E., & Brown, N. J. (2003) · Circulation · doi:10.1161/01.cir.0000046268.59922.a4 · Cited by 96
Self-citation
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Cao, Z., Jia, Y., & Zhu, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081820 · Cited by 398
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study
Kang, D.-H., Park, S.-J., Shin, S.-H., Hong, G.-R., Lee, S., Kim, M.-S., Yun, S.-C., Song, J.-M., Park, S.-W., & Kim, J.-J. (2019) · Circulation · doi:10.1161/circulationaha.118.037077 · Cited by 340
How ACE inhibitors transformed the renin–angiotensin system
Bakhle, Y. S. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15045 · Cited by 41
Metadata
- Authors
- Hubers, S. A., & Brown, N. J.
- Venue
- Circulation
- Published
- 2016-03-15
- Volume
- 133
- Issue
- 11
- Pages
- 1115-1124
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2299395117
- Cited by
- 250
- References
- 6
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.